483 results about "Antigen epitope" patented technology

The invention belongs to the technical field of biological engineering and in particular is a heat-induced fusion expression recombinant plasmid of truncated GST protein and a process for preparation. The invention selects utility truncated GST188 protein which is composed of 188aa as a carrier, a pXXGST-1 recombinant plasmid which expresses short peptide fusion protein in an escherichia coli heat-induced expression system and a heat-induced type pXXGST-2 recombinant plasmid which is used to express comparison to realize the aim of synthesizing short peptide creatures, which is especially provided for scanning, drawing, positioning antigen linear epitopes and identifying epitope motif. Experiments of the invention prove the adaptability and the applicability of the GST188 core protein which is used as the short peptide creatures expression vector, in antigen epitope scanning identification, and in particular when anti- recombinant target protein antiserum is used to indentify the epitope motif.

The invention relates to the field of fluorescence immunochromatography technique in medical immunology, specifically to a procalcitonin detection kit and a procalcitonin detection method. The detection kit is provided with a test cassette and is characterized in that the test cassette is successively provided with, from bottom to top, a PVC plate, a sample pad, a combination pad, a cellulose nitrate film and a water-absorbing pad, wherein a procalcitonin monoclonal antibody labeled by a rare earth fluorescent microsphere is adsorbed on the combination pad, the rare earth fluorescent microsphere has a diameter of 60 to 120 nm, is doped by rare earth lanthanide, is stable in a ground state and emits fluorescent light with a wavelength in a range of 540 to 600 nm under the action of an excitation light source in a wavelength range of 340 to 380 nm, and the monoclonal antibody is a purified mixed monoclonal antibody and is originated from monoclonal antibody cell strains directed at 2 to 6 different procalcitonin antigen epitopes. The procalcitonin detection kit has the advantages of simple operation, rapid reaction, high sensitivity, strong specificity, etc.

The invention discloses a recombinant novel coronavirus as well as a preparation method and application thereof. The invention firstly discloses a recombinant virus. Any one of an NS gene of an influenza virus, an HA gene of the influenza virus and an NA gene of the influenza virus of the recombinant virus is replaced. The invention further discloses application of the recombinant virus in preparation of a product for preventing and / or treating diseases caused by influenza virus and / or SARS-CoV-2. According to the invention, the SARS-CoV-2 antigen epitope and the influenza virus genome are operated from the gene level; the recombinant SARS-CoV-2 vaccine strain taking the influenza virus as the carrier is prepared on the basis of an RG technology, so that the problem of SARS-CoV-2 vaccine shortage is solved. The recombinant novel coronavirus will be a new milestone in the field of coronavirus vaccines, and the SARS-CoV-2 chimeric vaccine can protect more people from being harmed by theinfluenza virus and SARS-CoV-2.

The invention discloses a pig foot-and-mouth disease virus O-type broad spectrum multi-epitope recombination antigen and application thereof and belongs to the field of biological vaccines. The pig foot-and-mouth disease virus O-type broad spectrum multi-epitope recombination antigen adopts a strategy of an antigenized antibody, after main antigen epitopes of a plurality of strains of pig foot-and-mouth disease virus O-type are connected in series reasonably, the plurality of strains of pig foot-and-mouth disease virus O-type are coupled with a pig intravenous gamma globulin (IgG) heavy chain constant region to construct the pig foot-and-mouth disease virus O-type broad spectrum multi-epitope recombination antigen, and after ration through a Bio-Rad protein ration kit, the pig foot-and-mouth disease virus O-type broad spectrum multi-epitope recombination antigen and recombination foot-and-mouth disease virus 3D protein are matched to prepare the vaccines. Animal immunity testing results show that the vaccines can stimulate an organism to generate high-titer protective antibodies when the vaccines are used independently or matched with the recombination foot-and-mouth disease virus 3D protein to be used, an antibody level is higher than a national standard, and good application prospects are achieved.

The present invention discloses a T cell receptor, which specifically binds to a KRAS gene codon 12 mutation G12D 26aa peptide, wherein the amino acid sequence of the peptide is represented by SEQ IDNO:1 MTEYKLVVVGADGVGKSALTIQLIQN, the 9-12aa epitope polypeptide with high affinity is represented by SEQ ID NO:48 VVVGADGVGK and SEQ ID NO:49 KLVVVGADGVGK when the T cell receptor can identify the HLAmolecule antigen complex, and the HLA molecule is HLA-A0301. The invention discloses the amino acid sequences of the alpha chain and the beta chain of the T cell receptor in the identification of theantigen complex formed by the KRAS gene G12D mutation peptide and the HLA-A0301, nucleotide sequences encoding the alpha chain and the beta chain of the T cell receptor, a vector containing the nucleotide sequences, cells containing the nucleotide sequences, and applications of the vector or the cells in preparation of drugs for prevention and treatment of diseases related to KRAS gene mutation.

The invention discloses a monoclonal antibody with a liver cancer resisting activity and application thereof. The monoclonal antibody can perform specific binding with glypican-3 (GPC3) antigen epitope; and the amino acid sequence of the GPC3 antigen epitope is 359th-580th amino acid residue from an amino terminal with Gen Bank accession Number of AAA98132.1. In the invention, a high-valence high-specificity mouse-anti-human GPC3-C monoclonal antibody with an immunological activity and a cancer cell poisoning activity is prepared, thereby establishing an experimental foundation for studying expression and distribution of GPC3 in tissues and cells, deeply studying biological function of GPC3 protein and early detecting liver cancer in clinic and providing a non-toxicity auxiliary medicament.

The invention relates to the technical field of fluorescence immunochromatography in medical immunology and particularly relates to a D-dimer detection kit and a D-dimer detection method. The D-dimer detection kit is provided with a test paper card and is characterized in that the test paper card is sequentially provided with a PVC plate, a sample mat, a combination mat, a nitrocellulose membrane and a water absorption mat from bottom to top, wherein a D-dimer monoclonal antibody marked with rare-earth fluorescent micro-spheres is adsorbed on the combination mat, the diameter of each rare-earth fluorescent micro-sphere is 60nm to 120nm, the rare-earth fluorescent microspheres are doped with a rare-earth lanthanide element, the rare-earth fluorescent microspheres are stable at a ground state, and the fluorescence with wavelength range of 540nm to 600nm can be transmitted under the effect of a 340nm-380nm excitation light source; the monoclonal antibody is a monoclonal antibody mixed after purification and is sourced from a monoclonal antibody cell line aiming at 2 to 6 different D-dimer antigen epitopes. The D-dimer detection kit has advantages of simplicity in operation, rapid reaction, high sensitivity, high specificity and the like.

The invention provides a novel coronavirus antigen epitope and application thereof. A super computer is used for simulating S, E, M and N protein structures of the novel coronavirus, and novel coronavirus epitopes SEQ ID NO 1-38 are obtained through calculation. The epitopes have very good immunogenicity; an antibody generated by inducing a part of epitope polypeptide has the effect of neutralizing the novel coronavirus; the antigen epitope can be combined with antibodies in serum of novel coronavirus patients at home and abroad, has the potential of resisting various novel coronavirus strains, and also has the potential of identifying and applying different strains. The epitope provided by the invention can be used for (1) research and development of novel coronavirus vaccines and universal coronavirus vaccines such as MERS viruses and SARS viruses; and (2) preparing a novel coronavirus antibody, and further detecting and typing viruses and treating diseases caused by the viruses. Thenovel coronavirus antigen epitope has a wide application prospect in the aspects of prevention of coronavirus and propagation and outbreak thereof, and detection and diagnosis of virus strains.

The invention discloses a foot and mouth disease virus non-structural protein antibody enzyme-linked immunodetection kit. The kit comprises a foot and mouth disease virus non-structural protein 3B antigen epitope peptide-coated polymerase chain reaction plate and an enzyme-labeled antibody, wherein the foot and mouth disease virus non-structural protein 3B antigen epitope peptide is a polypeptide shown as a sequence 1 in a sequence table. The kit adopts a chemical synthesis non-structural protein 3B antigen peptide coated reaction plate and is small in antigen amount, high in sensitivity and high in specificity, and whether the foot and mouth disease virus infection exists can be efficiently detected. The kit is high in specificity, sensitive and high-efficiency and has good market prospects.

A yolk antibody for SARS coronavirus is prepared through injecting the antigen, which may be recombinant genetic protein S, M, or E,or the antigen epitope for said protein able to represent SARS coronavirus, or the synthetic polypeptide of said protein, etc, in health hen for primary immunizing, booster immunizing, collecting its egg, extracting yolk, and extracting the yolk antibody from it. It can also be prepared to become liquid preparation. It can be used to prevent SARS.

The invention discloses a method for separating an antigen-specificity T cell and cloning and encoding an antigen-specificity TCR gene from the antigen-specificity T cell. The invention also providesa nucleic acid molecule of the TCR for encoding the specificity of an HBV surface antigen S183-91, and a carrier containing the nucleic acid molecule. The TCR disclosed by the invention can be combined with an HBV S183-91 antigen short peptide complex FLLTRILTI-HLA*A0201; meanwhile, a cell of the TCR disclosed by the invention is transduced, can be specifically activated, and has a strong killingeffect on target cells.

The present invention belongs to molecular immunology field, mainly relating to chicken infectious bursal disease virus IBDV VP2 polypeptide fragment, more specificly relating to B cell antigen epitope polypeptide fragment in VP2 protein. The present invention also relates to IBDV VP2 protein neutrality and uses of B cell antigen epitope in preparing immunogen, immune animal, immune protection and uses for detecting antibody of resisting chicken infectious bursal disease virus IBDV or polypeptide of chicken infectious bursal disease virus IBDV. Animal is immunized by immunogen or vaccine designed according to B cell antigen epitope which can neutralize chicken IBDV VP2 protein and can produce antibody for neutralizing IBDV in vitro or vivo, so the immunogen can prevent virus infection to animal. Chicken IBDV VP2 protein neutralized B cell antigen epitope vaccine can prevent infection of chicken IBD classic toxic strain, superstrong toxic strain or / and variant toxic strain.

The invention discloses an O type foot-and-mouth disease virus variant as well as a coding gene and application thereof. In the invention, an O type foot-and-mouth disease virus pan-Asia strain O / YS / CHA / 05 is firstly separated out, the nucleotide sequence of the O type foot-and-mouth disease virus pan-Asia strain O / YS / CHA / 05 SEQ ID NO: 1, and the amino acid sequence is SEQ ID NO: 2. In comparison with a VP1 amino acid sequence, the virus strain has 7 variable sites, five of which are centralized in a G-H ring. Mutation of the sites ensures that the virus variant has the capability of escaping from host immunity so as to have the superiority for becoming a popular virus strain. Therefore, the variant can be employed to prepare an inactivated vaccine for prevention and treatment of the variant and relevant strains, dominant antigen epitope of the variant can be employed to prepare a synthetic peptide vaccine, and the variant can be employed to develop novel O type foot-and-mouth disease virus vaccines such as VLP vaccine and the like. Therefore, the invention has important value in controlling the popularity of O / YS / CHA / 05 and relevant variable strains.

The invention relates to screen for antigen epitope polypeptide, and building up of immunology detection method and the manufacturing and application for reagent for clinical diagnosis, especially for alpha-cyst albumen antigen epitope polypeptide.

The present invention relates to molecular immunology technology, and aims at screening out antigen epitope molecular simulation peptide capable of exciting human body's protective immunoreaction against tubercle bacillus, researching protective immunoreaction mechanism against tuberculosis, and further developing new type of concatenate polyepitope tuberculosis vaccine. The present invention provides one kind of antigen epitope molecular simulation peptide capable of exciting human body's protective immunoreaction against tubercle bacillus, and the peptide contains the amino acid sequence selected from SEQ ID Nos. 2, 5, 10, 12, 14 and 15. The present invention also provides the screening process and use of the peptide. The present invention may be used in preventing and controlling tuberculosis.

The invention discloses an antibody humanization transformation method. The antibody humanization transformation method comprises the following steps: analyzing an antibody gene sequence; starting antibody Fab isogeny modeling and optimization; ascertaining humanization mutation locus by epitope scanning, simulating virtual mutation molecular dynamics, and confirming key amino acid; the antibody humanization transformation method designs reasonable humanization antibody through the analysis, and further uses the epitope to scan and authenticate antibody humanization degree; and finally authenticates the appetency of the humanization antibody in a biological experiment. The antibody humanization transformation method has the advantages that the antibody humanization transformation method can be used for humanization transformation of mouse sources or source antibodies of other animals, only needs to provide the gene sequence of the antibody Fab, and is not dependent on information of antigen epitope. The humanization antibody designed by the antibody humanization transformation method has higher appetency maintenance, higher humanization degree, is capable of solving a contradiction between antibody appetency and humanization degree to a maximum degree.

The invention discloses an anti-human PD-L1 antibody with high affinity, high specificity and multiple antigen recognition epitopes and having higher functionality. The PD-L1 monoclonal antibody can be specifically combined with PD-1, and can effectively block combination of PD-L1 and PD-1 protein, specifically relieve immune negative regulation of PD-L1, and activate T cell secretory cell factors. All the functions can reach a currently unique level of PD-L1 targeted drug Tecentriq (MPDL3280A), and partial antibodies have greater diversity by being different from epitope of Tecentriq. One PD-L1 antibody can promote combination of PD-L1 with PD-1 protein, but can still relieve immune negative regulation of PD-L1, and activate T cell secretory cell factors.

The invention discloses a set of epitope polypeptides, particularly relates to a neutralizing B cell epitope sequence of encephalitis B virus E protein, and further discloses application of controlling and diagnosing encephalitis B virus by these epitopes. The amino acid sequences of the epitope polypeptides in the invention are respectively any amino acid sequence of SEQ ID NO: 64, SEQ ID NO: 79, SEQ ID NO: 95, SEQ ID NO: 108, SEQ ID NO: 124 and SEQ ID NO: 139. After the epitope polypeptides in the invention are coupled or fused with carrier proteins to be expressed as immunogenic or vaccine immuno animal organism, neutralizing antibodies aiming at JEV can be generated, and the JEV can be neutralized in vivo or in vitro so as to prevent virus from infecting animal organism. The epitope polypeptides in the invention or the junctional complex thereof can be used as reagents for detecting encephalitis B virus antibodies or encephalitis B virus polypeptide antibodies.

The invention relates to a fusion protein for preventing brucella infection and a preparation method and application of the fusion protein. In particular, the invention relates to a fusion protein, which contains brucella L7 / L12 protein ORF, a subunit of a brucella BLS protein, a T cell antigen epitope and a purification tag. The invention also relates to the preparation method and the medicinal application of the fusion protein.

The invention discloses a novel coronavirus T cell epitope peptide, pMHC and the preparation and application thereof. The amino acid sequence of the novel coronavirus T cell epitope peptide is as shown in any one of SEQ ID NO: 1-9. According to the invention, nine novel coronavirus T cell epitope peptides are discovered; the pMHC compound monomer is prepared by using the pMHC compound; the pMHC complex polymer can be used for detecting antigen-specific T cells in peripheral blood of a novel coronavirus infected rehabilitative person and used for an in-vitro T cell activation experiment, and the novel coronavirus T cell epitope peptides can be applied to immunodetection related to novel coronaviruses.

This invention provides a B cell epitope peptide and its identification method to neutralize helicobacterpylori urease B subunit, determines the antigen epitope corresponding with the monoclonal antibody 6E6 of helicobacterpylori urease B subunit, and confirms this B cell epitope is specific for the 6E6. The invention also provides a chimeric epitope vaccine and its preparation method containing B cell epitope and carrier protein BSA, and the B cell epitope has strong antigenicity.

The invention discloses lymphocyte antigen epitope peptides and application thereof, belongs to the fields of medical immunology and infectious diseases, and particularly relates to 164 thymus dependent lymphocyte antigen epitope peptides of five proteins of SARS-CoV-2 and application thereof. The antigen epitope peptides can be presented by HLA-A molecules to stimulate activation, proliferation and differentiation of SARS-CoV-2 specific thymus dependent lymphocytes, so that the immune effect of resisting SARS-CoV-2 infection is exerted. The antigen peptides can be used for preparing mixed polypeptide vaccines of SARS-CoV-2, recombinant protein vaccines connected with a plurality of epitope peptides in series and DNA and RNA vaccines, can be used for preparing a detection kit for detecting SARS-CoV-2 specific thymus dependent lymphocytes, can also be used for preparing effector thymus dependent lymphocytes or drugs for treating SARS-CoV-2 infection, and have a potential application value in the prevention, treatment and diagnosis of SARS-CoV-2 infection and COVID-19.

The invention discloses a PEDV S gene major antigen epitope serial connection recombination gene, and a preparation method and an application thereof, and belongs to the field of a PEDV S protein major neutralizing epitope region efficient expression method. The PEDV S gene major antigen epitope serial connection recombination gene is obtained through connecting three major antigen epitopes of a PEDV S gene in series; every two major antigen epitopes are connected through a flexible amino acid base sequence; the name is S123; and the sequence of the base sequence is shown as SEQ ID NO:1. The recombination gene contains most PEDV antigen epitopes; the selected fragments avoid a high-variation region; the expression quantity is efficient and stable; the immunogenicity is high; when the application of PEDV S gene major antigen epitope serial connection recombination protein to a PEDV indirect ELISA detection kit is used, the PEDV can be fast diagnosed; and the swinery neutralization protection can be well monitored and evaluated.

The invention relates to a test reagent box of multiple antigen membrane method which is used for diagnosing RA, it includes tablets and response groove, the tablets hold on the response groove; the tablets gap corresponding to the response groove gap; there is multi-personal reaction zone on the tablets which correspond with the multi-groove of reaction groove, there is a gap on the top of each groove; membrane bar test paper adhere to each reaction zone and with RA correlate antigen and response control belt; the RA related antigen is the corresponding antigen of RF, anti-CCP, anti-RA-33 antibody, anti-Sa antibody, anti-P68 or more than four kinds of antigen in antigen epitope polypeptide or antigen epitope polypeptide, the response control belt is a mixture of man IgG and man IgM. The reagent box in this invention overcome the lack of detection sensitivity and Specificity of the single autoantibody and the red tape of several autoantibody detection in a single operation, it provide the accuracy and convenience of RA diagnosis. The invention also disclosed the method of how to make the test box.

The invention belongs to the technical field of biology, and discloses a novel coronavirus multi-epitope recombinant antigen and a preparation method thereof. The recombinant antigen comprises a plurality of dominant antigen epitopes of the novel coronavirus, a CHO cell preferred codon is adopted to convert the amino acid sequence of the recombinant antigen into a corresponding nucleotide sequence, the nucleotide sequence is chemically synthesized, and a recombinant expression vector is constructed, so that the expression quantity of the recombinant antigen in the CHO cell is increased. In addition, it is verified that the recombinant antigen can generate immunological reaction with mouse serum obtained through immunization of different antigens of the novel coronavirus.

The invention discloses a method for detecting beta conglycinin, the monoclonal antibody special therefor, and the kit. The kit for detecting beta conglycinin comprises beta conglycinin monoclonal antibody or polyclonal antibody, wherein the monoclonal antibody or the polyclonal antibody is obtained with the conjugate of beta conglycinin hapten and carrier protein as immunogen; and the beta conglycinin hapten is the antigen epitope peptide on alpha subunit of beta conglycinin molecule. Experiment proves that the beta conglycinin monoclonal antibody prepared by the invention method has high potency, high affinity, and strong reaction specificity, and can highly bond with the beta conglycinin without cross reaction; and when the monoclonal antibody of the invention is used for detection, itis possible to obtain wide detection range (0.002 mu g / ml-1.000 mu g / ml), high sensitivity (0.002 mu g / ml), and small coefficient of variation. The hybridoma of the invention can stably produce monoclonal antibody, thus the detection method and the monoclonal antibody special therefor of the invention are applicable to the detection of beta conglycinin in grain food, animal feed, and the like.

According to the invention, the cellular immune antigen dominant epitopes of four important structural proteins p30, p54, p72 and CD2v of ASFV are screened, and the corresponding enzyme-linked immunospot test methods are established. The screened polypeptides have high amino acid sequence conservation, can effectively induce ASFV specific cellular immune response, and can be used as candidate immunogens for ASFV epitope carrier vaccines. The T cell epitope polypeptides of ASFV structural proteins obtained by the invention are screened, and the corresponding ELISPOT detection methods are established. The invention provides a powerful tool for efficacy evaluation of the ASFV candidate vaccines, and also lays a foundation for the research and development of ASFV polypeptide carrier vaccines.

The invention discloses SARS-CoV-2 antigen polypeptides and application thereof. The invention relates to four SARS-CoV-2 polypeptide antigens and application thereof. The amino acid sequences of thefour SARS-CoV-2 polypeptide antigens are SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4 or derivative sequences thereof. The epitopes screened out in the invention can be used for detecting anSARS-CoV-2 virus antibody, are high in specificity and accuracy, have an application value in clinical diagnosis, and play a positive and effective role in preventing and controlling SARS-CoV-2 virusinfection.

The invention discloses antigen epitope peptide of alpha fetoprotein, wherein an amino acid sequence of the antigen epitope peptide is an amino acid sequence (1) shown as SEQ ID NO: 1, an amino acid sequence (2) shown as SEQ ID NO: 3 or an amino acid sequence which is formed by deleting, adding and / or substituting one or more amino acids for the amino acid sequence (1) or (2) with unchanged function of the antigen epitope peptide of the alpha fetoprotein. The invention also discloses a nucleotide sequence for coding the antigen epitope peptide of the alpha fetoprotein and a preparation methodthereof. The nucleotide sequence comprises a recombinant vector of the nucleotide sequence, a recombinant host cell of the recombinant vector, a monoclonal hybridoma cell and a monoclonal antibody and comprises a kit for detecting the alpha fetoprotein of the antigen epitope peptide and / or the monoclonal antibody. The antigen epitope peptide of the alpha fetoprotein has high specificity; and the kit for detecting the alpha fetoprotein prepared by the monoclonal antibody obtained by the antigen epitope peptide has high sensitivity.

The invention belongs to the biological medicine field, relates to recombinant fusion protein and use thereof, and in particular relates to recombinant fusion protein carrying hepatitis B virus therapeutic antigen epitopes which are inserted into hepatitis B core antigen protein particles or truncated fragments and use thereof. The recombinant fusion protein contains multiple epitope antigens of hepatitis B virus (HBV) and other immune stimulating epitope antigens and hepatitis B core antigen virus-like particles or truncated fragments thereof for preparation of chimeric antigen, the multiple antigen epitopes can be inserted into same or different sites of hepatitis B virus core antigen HBc or truncated fragments thereof in the manner of single epitope or multi epitope combination, and by combination with different adjuvants, HBV specific humoral and cellular immune functions can be strengthened.